Redox regulation of DUBs and its therapeutic implications in cancer

Apooori Tyagi, Saba Haq, Suresh Ramakrishna

ABSTRACT

Reactive oxygen species (ROS) act as a double-edged sword in cancer, where low levels of ROS are beneficial but excessive accumulation leads to cancer progression. Elevated levels of ROS in cancer are counteracted by the antioxidant defense system. An imbalance between ROS generation and the antioxidant system alters gene expression and cellular signaling, leading to cancer progression or death. Post-translational modifications, such as ubiquitination, phosphorylation, and SUMOylation, play a critical role in the maintenance of ROS homeostasis by controlling ROS production and clearance. Recent evidence suggests that deubiquitinating enzymes (DUBs)-mediated ubiquitin removal from substrates is regulated by ROS. ROS-mediated oxidation of the catalytic cysteine (Cys) of DUBs, leading to their reversible inactivation, has emerged as a key mechanism regulating DUB-controlled cellular events. A better understanding of the mechanism by which DUBs are susceptible to ROS and exploring the ways to utilize ROS to pharmacologically modulate DUB-mediated signaling pathways might provide new insight for anticancer therapeutics. This review assesses the recent findings regarding ROS-mediated signaling in cancers, emphasizes DUB regulation by oxidation, highlights the relevant recent findings, and proposes directions of future research based on the ROS-induced modifications of DUB activity.

1. Introduction

Organisms are adapted to the atmospheric environment containing approximately 80% nitrogen and 20% oxygen and have evolved to maintain a balance between oxidants and antioxidants [1]. Free radicals are chemical species that possess one or more unpaired electrons in their outer shell [2-5]. There are two major species of free radicals: reactive oxygen species (ROS) derived from oxygen and reactive nitrogen species (RNS) derived from nitrogen and oxygen [1]. Oncogenic transformation is commonly associated with a shift in redox balance to a higher oxidized state in many cancer types, including breast, liver, bladder, colon, and ovarian cancers [6-8]. The combination of environmental and internal factors has an additive effect on cellular ROS levels in oncogenic transformed cells. Higher levels of ROS disrupt the redox balance and homeostasis, resulting in severe damage to various cellular components such as DNA, lipids, and proteins, which have implications in many diseases including cancer [9,10].

Post translational modifications (PTMs) act as a molecular switch to activate or deactivate the molecular function of their target proteins. For instance, during cell signaling events, the reversible addition or deletion of phosphate groups modulates the activity of kinases [11], and ubiquitination marks cyclins for destruction at defined time points during the cell cycle [12,13]. There are several categories of PTMs, including phosphorylation, acetylation, and methylation, which have been implicated in many cellular processes, including the regulation of enzyme activity, protein stabilization, protein localization, and protein degradation [14,15]. The most widely studied PTM is the regulation of protein dynamics by the conjugation or removal of ubiquitin (Ub) from target proteins with the help of enzymes central to ubiquitination and deubiquitination processes [16-21].

The ubiquitin-proteasome system (UPS) regulates protein turnover of their substrates implicated in different cellular processes including the cell cycle, DNA repair, and cell apoptosis [22,23]. Importantly, the enzymes responsible for ROS production are also known to undergo 26S...
proteasomal degradation [24–26]. However, the regulation of deubiquitinating enzymes (DUBs) that reverse the process of protein ubiquitination of ROS-generating enzymes is an equally important process that has not been given much attention. In this review, we mainly discuss the ROS-mediated regulatory functions of DUBs and their role in cancer progression.

2. ROS generation

Intracellular ROS generation is induced by various endogenous and exogenous agonists. Signalling-associated ROS is generated mainly inside the mitochondria or by growth factor signaling through the activation of NADPH oxidase enzyme (NOX). Mitochondria are a major site of ROS generation inside mammalian cells [27–29]. The mitochondrial electron transport chain (ETC) produces superoxide as the proximal ROS, which exists in the anionic form and is highly membrane impermeable [30]. The superoxide is dismutated into H$_2$O$_2$ either in the mitochondrial matrix (by MnSOD) or in the cytosol (by Cu/ZnSOD) [31, 32]. The ETC encompasses five multi-subunit protein complexes (complexes I-IV and F$_1$–F$_0$ ATP synthase) as well as the mobile electron transporters ubiquinone and cytochrome c [33–35]. The sequential transfer of electrons is designed to prevent electron escape, but any delay at one location generates traffic and causes electron leakage inside cells [36]. These electrons leaking from the ETC react with oxygen and generate ROS inside cells, affecting various signaling pathways involved in the cell cycle and proliferation.

Under stress conditions, there are several oncogenes such as MYC, RAS, PI3K-AKT-mTOR and BCR/ABL, that are involved in modulating ROS-producing capacity of the ETC by increasing electron flow either by fueling the TCA cycle with carbon sources or by destabilizing electron flow through the ETC. These oncogene-mediated mechanisms reset ROS levels to a higher homoeostatic set point, sustaining the cancer cell phenotype [37–39]. For instance, MYC induces mitochondrial transcription factor A (TFAM) resulting in increased mitochondrial biomass and oxygen consumption indicating enhanced ETC activity [40]. RAS decrease complex I activity in digitonin-permeabilized fibroblasts by destabilizing the ETC, resulting in inefficient electron flow and ROS production [41]. Likewise, BCR/ABL impairs electron flow between ETC complexes I and II and complexes II and III resulting in increased ROS production [42].

The NOX and dual oxidase (DUOx) family of enzymes is another important endogenous source of ROS in a variety of tissues [43–45]. NOX genes confer antagonistic pleiotropy and generate ROS as part of normal physiological functions, including signal transduction and biochemical reactions [46]. The NOX/DUOX-mediated generation of ROS involves activation of genes and transmembrane proteins that transfer electrons from NADPH to molecular oxygen, generating superoxide as the center for ROS production. NOX-derived ROS have a predisposition for causing molecular damage and are associated with chronic diseases such as hypertension, Alzheimer’s disease, atherosclerosis, diabetic nephropathy, and cancer [46–48]. There is another major site of ROS generation inside cells via peroxisomes, where molecular oxygen is reduced to H$_2$O$_2$ and ultimately to H$_2$O through ROS-metabolizing enzymes such as xanthine oxidase [49]. Endogenous and exogenous components such as prostanoids, fatty acids, and drugs also produce free radicals, especially HO$_2^*$, inside cells [50].

3. The dual nature of ROS in cancers

Cancer cells exhibit higher ROS levels compared to their normal counterparts, producing elevated levels of antioxidant proteins to detoxify ROS and maintain redox homeostasis. Depending upon the cellular levels and duration of exposure, ROS have been shown to affect DNA, proteins, and lipids and activate oncogenic signaling cascades leading to genomic instability. Hydroxyl ions generated via the Fenton reaction result in DNA lesions such as oxidized DNA bases and single- or double-strand breaks [51–53]. ROS target lipids by reacting with polyunsaturated fatty acids to initiate lipid peroxidation [54,55]. The oxidation of lipids generates several genotoxic compounds, such as 4-hydroxy-2-alkenals, malondialdehyde, and 2-alkenals, which induce the formation of DNA adducts and cause DNA damage [56,57]. Moreover, ROS-induced lipid peroxidation might serve as a clinical marker in cancer progression. Higher lipid peroxidation and detection of thiobarbituric acid-reactive substances in the serum of colorectal carcinoma patients indicate increased peroxidation in tumor [58].

ROS influence the tumor microenvironment by regulating several cellular events in cancer, such as angiogenesis, metastasis, and maintenance of tumor stemness [10,59–62]. ROS regulate angiogenesis in tumors by the upregulation of vascular endothelial growth factor (VEGF) receptors or various angiogenic signaling cascades, such as PI3K/AKT and MAPK pathways [62–64]. In highly metastatic tumors, accumulated levels of ROS promote cancer invasion and metastasis [65]. ROS also regulate epithelial to mesenchymal transition (EMT) responsible for tumor metastasis. The NOX-dependent NF-$\kappa$B signaling pathway enhances TGF-$\beta$1 and MMP expression to promote migration and invasion of MCG-10A and MDAMB-231C cells [66]. Treating colon carcinoma cells with ROS increases the production of MMP1/2/7/9 to enhance metastasis [67]. Oxidative stress can lead to chronic inflammation and cancer progression via activation of transcription factors, such as HIF-1$\alpha$, $\beta$-catenin/Wnt and NF-$\kappa$B [68–70]. ROS-mediated activation of NF-$\kappa$B induces chemotherapeutic resistance against a variety of drugs, such as doxorubicin, cisplatin, and tamoxifen, through upregulation of B-cell lymphoma-extra-large (Bcl-xl), B-cell lymphoma 2 (Bcl-2), Akt, and X-linked inhibitor of apoptosis (XIAP) [71–73].

Paradoxically, ROS can also induce cancer cell death in biological systems, which can be exploited in cancer therapeutics [74–76]. Increased levels of intracellular ROS induce cancer cell senescence and apoptosis through a family of aspartate-directed and Cys-dependent proteases known as caspases [77–79]. In many cell types, H$_2$O$_2$ mediates the activation of autophagy through a beclin-1-dependent manner but can also induce autophagy, independent of beclin-1 in glutathione-depleted RAW264.7 cells [80]. In transformed U87 and HeLa cells, but not in non-transformed normal mouse astrocytes, H$_2$O$_2$ induces autophagy-mediated cell death [81]. Overall, enhanced ROS signaling has been implicated in cancer progression as well as cancer cell death.

3.1. ROS-mediated signaling pathways in cancer

An upsurge in ROS-sensitive signaling pathways is observed in different cancer types, leading to tumor growth and malignant progression. Such ROS-mediated oncogenic progression results either by the activation of several oncogenic pathways or through oncogenic mutations [82–85]. Here, we have briefly discussed the relevant signaling pathways mediated by ROS in cancer.

3.1.1. Nuclear Factor Kappa-B pathway

Nuclear Factor Kappa-B (NF-$\kappa$B) is a redox-regulated sensor for oxidative stress that undergoes activation under low doses of H$_2$O$_2$ [86]. NF-$\kappa$B is essential to cancer cell survival, proliferation, and cell cycle regulation along with the development of drug resistance [87]. Cytokine-based NF-$\kappa$B stimulation activates the IxB kinase complex (IKKs) that phosphorylates NF-$\kappa$B inhibitor (IxB), resulting in its ubiquitination and subsequent proteolysis. The IKK-mediated degradation of IxB releases bound NF-$\kappa$B, which translocate to the nucleus and induces the expression of anti-apoptotic and anti-inflammatory genes [88,89]. The IKK-based NF-$\kappa$B-inducing signaling process is activated by increased cellular oxidative stress [90,91]. Treating MCF-7 cells with TNP-$\alpha$, IL-1$,\beta$, or sodium arsenite generates free radicals that activate NF-$\kappa$B and enhance cellular proliferation [92]. Knockdown of ROS scavenging enzyme, SOD increases the cellular levels of ROS and NF-$\kappa$B activity in oral carcinoma cells [93]. RAC1-mediated ROS production
and NF-κB activation were found to facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation [94].

3.1.2. Phosphoinositide-3-kinase/AKT signaling
The phosphoinositide-3-kinase (PI3K)/AKT pathway regulates many critical cellular functions, including cell cycle progression, protein synthesis, autophagy, angiogenesis, and drug resistance [95–97]. The binding of ligands, such as VEGF, epidermal growth factor (EGF), and IL-6, to receptor tyrosine kinase activates class I PI3K. The activated PI3K produces phosphatidylinositol 3,4,5 triphosphate (PIP3) from phosphatidylinositol 4,5 bisphosphate (PIP2), which is reversed by tumor suppressor phosphatase and tensin homolog (PTEN) through the phosphorylation circuit [98,99]. Deregulation of PI3K/AKT signaling through ROS has been reported in various cancers [100–102]. ROS directly or indirectly activate PI3Ks either by amplifying various downstream signaling cascades or inhibiting the activity of PTEN. ROS promote the phosphorylation and proteolytic degradation of PTEN in breast cancer, glioblastomas, melanoma, and endometrial cancer [103–106]. H2O2 generated by EGF in human ovarian cancer activates AKT and its substrate p70S6K1 that regulates protein synthesis [107]. In breast cancer cells, PI3K/AKT signaling is upregulated by ROS generation through estrogen metabolism [108].

3.1.3. Mitogen-activated protein kinase/ERK pathway
The mitogen-activated protein kinase (MAPKs) play an important role in the transduction of signals required for cell survival [109]. Dysregulation of this crucial pathway has been linked to the pathogenesis of several cancer types. ROS act as a physiological modulator and activate MAP kinases extracellular signal-regulated kinase (ERK) 1/2 and p38 through various mechanisms, such as activation of Ras and p90RSK kinase [110–112]. Estrogen metabolism in breast carcinoma produces H2O2, which activates ERK1/2 and increases tumor growth [113]. Additionally, ROS initiate the oncosignle via activation of HRAS, NRAS, and KRAS [114,115]. In an animal model for Kras-driven pancreatic cancer, inhibiting cellular ROS levels using N-Acetyl-L-cysteine (NAC) and MitoQ reduced the progression of pre-cancerous lesions [115].

3.1.4. Signal transducer and activator of transcription pathway
The signal transducer and activator of transcription (STAT) pathway is associated with tumor formation and cell proliferation. STAT3 is activated in a number of malignancies and is the most extensively studied member of the STAT family in oncogenic signaling pathways. Unlike transient activation of STAT3 signaling in normal cells, many cancer types exhibit constitutively active STAT3 [116,117]. Several oncogenic pathways lead to STAT3, and many oncogenic and resistant tumors rely on ROS-mediated STAT signaling as an alternative mechanism for survival. Therefore, STAT3 serves as a therapeutic cancer target, and inhibiting STAT3 has the potential to block its upstream pathways and direct an apoptotic cancer cell fate [118–120]. In breast cancer cells, STAT3 inhibition using niclosamide inhibits BCL2 expression and sensitizes cancer cells. Radiotherapy treatment was shown to reduce ROS levels and increase phosphorylation of STAT3 in triple-negative breast cancer [121]. In acute myeloid leukemia, increased H2O2 level has been linked with FLT3/ITD expression in a NOX-dependent manner, leading to activation of STAT5 signaling. An FLT3 inhibitor (PKC412) and NOX inhibitors (DPI, VAS2870) are shown to regulate ROS levels in AML cells expressing FLT3/ITD [122]. Also, STAT5 expression and BCR/ABL mutation are associated with the progression of chronic myeloid leukemia (CML), where elevated STAT5 expression increases ROS production and BCR/ABL mutation in CML cells [123].

4. Ubiquitination and deubiquitination
The process of ubiquitination is an important PTM that involves the reversible covalent conjugation of ubiquitin moieties to substrate proteins to signal protein degradation, regulating their function. Ubiquitination is carried out by three enzymatic components that act in a sequential manner to attach mono-Ub or chains of Ub onto substrate proteins: (E1) Ub-activating enzyme, (E2) Ub-conjugating enzyme, and (E3) Ub-protein ligase. Lysine-48 (K48) along with K11- and K29-linked
Dysregulation of such a process results in many physiological abnormalities, such as cancer, inflammatory diseases, and neurodegeneration [139–142]. Due to the involvement of DUBs in several physiological processes, it is important to unravel the different layers of DUB regulation in cellular functions. Modulation of DUB activity has been accomplished recently, and there are studies showing that the activity of these proteases is modified post-translationally by ubiquitination, phosphorylation, and SUMOylation [130,143–145]. In addition, the activity of DUBs also depends on the presence of scaffold proteins or substrates that impart conformational change towards catalytic competency [146,147]. Similar to other proteases like protein tyrosine phosphatases (PTPs), the activity of DUBs inside cells has been carefully monitored to avoid spurious cleavage of proteins; however, the development of reactive molecules to modify DUB function and related pathways is a new area that needs extensive research.

5. ROS-mediated regulation of DUB catalytic activity

The catalytic activity of many enzymes is carried out by a Cys residue present at the enzyme’s active site. The regulation of enzyme activity by reversible oxidation of active site Cys residues is an intense area of research. The thiol group in Cys presumably is deprotonated first [148] and can adopt different oxidation states. This directs catalytic Cys to be a good target for oxidative control. Most DUBs along with E1 and E2 enzymes and some E3 ligases have catalytic Cys in their active site and tend to undergo ROS-mediated regulation.

Oxidation of proteins is considered a signature of permanent damage and is related to aging, cancer, and other chronic conditions. Cellular machinery and degradation pathways operate in unison to remove such damaged proteins from the cellular system. However, under conditions of stress, few Cys amino acid residues undergo reversible oxidation to modify protein activity in a manner analogous to protein regulation by phosphorylation [149]. Strikingly, it was found that Cys enzymes can be rapidly targeted by oxidative stress. Mechanistic and structural analysis revealed that ROS target catalytic Cys with low pKa values that are present more frequently in the active sites of enzymes [150,151]. The presence of catalytic diads or triads in Cys-dependent DUBs renders them more susceptible to oxidation. In the active site, histidine (His)
residues lower the pKa of nucleophilic Cys residues and activate them to disrupt the isopeptide linkage of a ubiquitinated substrate. Aspartic acid (Asp) or Asparagine (Asn) present in the triad align and polarize the His residue. Cys oxidation by H2O2 results in the formation of sulfenic (–SOH) acid, with one oxygen molecule in the reversible oxidized state of Cys. A combination of mass spectrometry, mutational analysis, and structural studies showed that reversible inhibition of DUB activity is due to sulfenic acid Cys intermediates at the enzymes’ active site [152]. Further oxidation of sulfenylated Cys leads to the irreversible formation of sulfonic (–SO3H) or sulfonic acid (–SO3H) acids with two or three oxygen molecules, respectively [153]. For this modification to function as a reversible switch, further oxidation to sulfonic and sulfonic acid (–SO3H and –SO3H) must be avoided (Fig. 2). There are mechanisms that prevent over-oxidation of prone Cys residues to irreversible oxidation states. Formation of a disulfide bridge between two nearby Cys residues [154] or the formation of a cystic sulfenamide as a result of a covalent bond formed between Cys and the main chain nitrogen of a neighboring residue [155,156] are two strategies by which this can be achieved.

Recent studies have portrayed oxidative and redox modification of DUBs as new aspects of further biological study. The majority of DUBs are Cys proteases and have a reactive Cys residue that is susceptible to reversible oxidation by ROS. Oxidation by ROS has been shown to inhibit sub-family members of DUBs, including USP, OTU, and UCH, both in vitro and in vivo [150]. In line, a reduction in overall DUB activity has been observed upon treatment of macrophages with exogenous and endogenous H2O2 [150]. Redox-driven DUB regulation is reversible, and even prolonged H2O2 exposure is unable to cause permanent DUB inhibition. Moreover, partial recovery of cellular DUB activity occurs in a time-dependent manner, even during H2O2 exposure, due to the upregulated activity of anti-oxidative genes in the cells [150].

6. DUBs and ROS regulation

The degree of DUB inhibition by ROS is specific for individual DUBs due to their differences in geometry and basal reactivity of their active sites. For example, partially active or inactive DUBs are less susceptible to Cys oxidation by ROS compared to fully active DUBs [143]. ROS-mediated regulation of several DUBs is discussed below.

6.1. USP1

USP1 is implicated in the DNA damage response and is critical for the maintenance of genomic stability [157,158]. It has been shown to deubiquitinate proliferating cell nuclear antigen (PCNA) and Fanconi anemia group D2 protein (FANCDD2) [159,160]. PCNA has a strong role in regulating the response to DNA damage, and mono-ubiquitination of PCNA is essential for translesion DNA synthesis (TLS) across damaged bases [161]. Upon exposure to DNA-damaging agents, such as ultra-violet (UV) irradiation and associated USP1 degradation, higher PCNA mono-ubiquitination has been observed [162,163]. Additionally, H2O2-treated cells also show high intracellular levels of mono-ubiquitinated PCNA, indicating H2O2-mediated inhibition of USP1 [164]. H2O2 does not affect the interaction of USP1 with its co-activator USP1-associated factor 1 (UAF1), suggesting that the inhibition is likely caused by oxidation of the USP1 active site [156,165]. Unlike UV irradiation and other DNA-damaging agents, this redox-dependent inhibition of USP1 is rapid and reversible [164] and can be rescued by certain reducing agents, such as diithiothreitol (DTT). Additionally, enhanced PCNA mono-ubiquitination by oxidative stress is most active during S-phase and nearly non-existent in G0 or G1-phase of the cell cycle. USP1 is responsible for fine-tuning the PCNA mono-ubiquitination-dependent DNA damage tolerance in response to oxidative DNA damage during S-phase [143].

6.2. USP7

USP7 is a deubiquitinating enzyme that regulates many substrates involved in diverse cellular processes, such as DNA replication, tumor suppression, epigenetics, and the immune response [166-168]. Despite the importance of this enzyme, regulation of USP7 activity is still not well understood. A study on the effect of ROS on USP7 showed that H2O2 reversibly oxidizes the catalytic Cys present in the active site of USP7. Temporal studies in U2OS cells showed fully recovered USP7 activity in 2 h after oxidative stress. The inhibition of reversible USP7 oxidation with DTT is suggestive of the occurrence of some but not all active site Cys residues in a reversibly oxidized state, i.e. sulfenic acid form, Cys-SOH [143]. ROS-mediated inhibition of USP7 is higher at basic conditions (pH 8.2 or 8.8) than at pH 7.4 [150]. USP7 is known to have a disheveled active site in the absence of substrate or co-factors [169]. Sensitivity to DUB oxidation by ROS requires the catalytic Cys residue to have low pKa. Altering the environment by increasing pH augments DUB sensitivity towards ROS by facilitating Cys deprotonation [170, 171]. Additionally, USP7 treatment with H2O2 in the presence of free ubiquitin having an unmodified carboxy-terminus led to increased sensitivity to ROS (~5 fold) similar to that caused by high pH condition [150].

6.3. USP19

USP19 is a member of the USP subfamily of DUBs and contains a C-terminal transmembrane domain. It is the first DUB reported to be regulated by heat shock protein, Hsp90, which binds with the catalytic domain of USP19 and promotes its substrate association. USP19 is involved in the endoplasmic reticulum-associated protein degradation (ERAD) pathway [172] that eliminates misfolded proteins from the endoplasmic reticulum of eukaryotic cells [173]. Additionally, hypoxia-inducible factor 1α (HIF-1α), a key player in the response to hypoxia, interacts with USP19 to prevent the degradation of HIF-1α in a non-catalytic manner [174]. USP19 contains several regulatory domains in addition to its conserved USP domain that harbors the catalytic active site in the mitochondrial glutaredoxin (Grx2a)-overexpressing cell line [185]. These studies provide a crucial association between oxidative stress and tumorigenesis through transcriptional downregulation of
tumor-regulating DUBs.

6.5. OTU sub-family DUBs

OTU DUBs are Cys proteases that cleave substrate polyubiquitin chains and can identify the associated linkage type [186,187]. The presence of Cys catalytic residues in the active site of OTU subfamily proteases makes them susceptible to reversible oxidation. Incubating purified OTUB1, OTUD1, OTUD2, OTUD3, OTUD5, and OTUD6A with \( \text{H}_2\text{O}_2 \) promoted -SOH modifications of these DUBs. Sulfenylation of OTU subfamily DUBs in response to varying concentrations of ROS indicated the ROS-mediated regulation of DUB activity [188].

Cezanne/OTUD7B has emerged as a negative regulator of NF-\( \kappa \)B signaling through its role in the negative feedback loop in response to pro-inflammatory signaling. The role of ROS in NF-\( \kappa \)B signaling is well understood, but their effects on the negative regulators of NF-\( \kappa \)B have not received much attention [189]. In epithelial or endothelial cells, cezanne is induced in response to TNF\( \alpha \), which negatively regulates NF-\( \kappa \)B translocation apart from its transcriptional activation. Cezanne functions at the level of the IkB kinase complex or upstream of TNF receptor (TNFR) signaling and prevents the degradation of RIP1 signal adapter protein [189]. However, the negative regulatory functions of Cezanne on NF-\( \kappa \)B can be suppressed by \( \text{H}_2\text{O}_2 \), which promotes the oxidation of Cys residues of cezanne and prolongs NF-\( \kappa \)B pathway activation in hepatocellular carcinoma cells. This ROS-mediated inactivation of cezanne was reversed by DTT treatment [193], suggesting the importance of oxidation-mediated regulation of cezzane activity in cancer.

A20 is also a well-characterized member of OTU Cys-proteases [186]. Several reports suggested that A20 has a dual behavior as both a pro-tumorigenic and an anti-tumorigenic enzyme in cancer progression [194]. The high-resolution crystal structure revealed a sulfenic acid intermediate in the catalytic site of A20 in four oxidation states, which are reversible and can establish a new mechanism to regulate DUB activity [188]. Otherwise, unstable hydroxylation intermediates (Cys sulfenic (–SOH) or sulfonic (–SO\( \text{H}_2 \)) acid) are alleviated by interactions within the OTU domain, preventing permanent inhibition from irreversible oxidation to sulfonic (–SO\( \text{H}_2 \)) or sulfonic (–SO\( \text{H}_2 \)) acid [188].

6.6. UCHL1

Ubiquitin C-terminal hydrolase 1 (UCHL1) is predominantly expressed in many cancers and its high expression is linked with poor prognosis [195]. Upregulated expression of UCHL1 has been observed in different cancers, including lung cancer patients having a smoking history [196,197], colorectal cancer [198], and lymphoma [199], suggesting its role as an oncogene. Transgenic murine models with upregulated UCHL1 showed the development of tumors in many tissues [199]. Additionally, UCHL1 expression led to increased metastasis and tumor phenotype whereas its depletion showed anti-tumor effects in a lung cancer cell line [196].

Apart from its oncogenic functions, UCHL1 is also a neuron-specific DUB that constitutes around 1–5% of total brain protein. UCHL1 can both ligate and hydrolyze ubiquitin from proteins as a part of recycling into the ubiquitin pool required for the proteasomal pathway [200]. There are several neuronal functions of UCHL1 wherein it interacts with axonal, cytoskeletal, and synaptic proteins. In rodents, mutations in UCHL1 result in axonal and white matter abnormalities, suggesting the importance of UCHL1 in synaptic and axonal function. Aberrations in UCHL1 have been associated with a number of neurodegenerative diseases, such as familial Parkinson’s disease and Alzheimer’s disease [201,202]. Reactive lipid species, such as prostaglandins, are associated with the pathogenesis of stroke and many brain diseases. Reactive prostaglandin metabolites, such as 15dPGJ2, disrupt the UPS and lead to accumulation of ubiquitinated proteins [203,204]. 15dPGJ2 alters the structure and function of UCHL1 [205] through the interaction between the \( \alpha \), \( \beta \)-unsaturated carbonyl center of the cyclopentenone ring of 15dPGJ2 and the thiol group present in Cys 152 of UCHL1. Additionally, 15dPGJ2 can potentially inhibit UCH-L1, leading to hypoxic neuronal death, whereas overexpression of UCH-L1 protects neurons from hypoxia [206].

The Cys at the 152nd position of UCHL1 assumes a pivotal role in neuronal survival following hypoxic or ischemic injury. Knock-in mice with mutations at the 152nd position, Cys substituted by alanine (UCHL1-C152A), revealed fewer Ub-protein aggregates than mice with wild-type UCHL1 [207]. Also, the oxidation of parkinsonism-inducing dopamine derivative 3’,4’DHhTNQ to its quinoid structure leads to its covalent conjugation to UCHL1 through Cys152 [202,207–209]. Thus, UCH-L1 modification by reactive lipid species highlights the potential significance of reversible oxidation in ischemic injury and neurodegenerative disease.

7. DUBs and cancer

The activity of DUBs is not limited to the removal of ubiquitin conjugates but encompasses multiple biological ramifications such as DNA repair, chromatin remodeling, cell-cycle control, and signaling pathways involved in cancer [7,17,130]. There are several lines of evidence that implicate the role of DUBs in tumor development at multiple levels that are briefly discussed below.

p53 is a tumor suppressor that is most frequently altered in several human cancers. p53 plays many pivotal roles including maintaining genome integrity, angiogenesis, autophagy, migration, aging, and apoptosis [210,211]. Many DUBs are directly or indirectly associated with p53 regulation. Ubiquitin-specific protease (USP) 7 and OTUB1 indirectly regulate p53 via suppression of Mdm2 and UbcH5s, respectively [166,212]. Compound 1, a selective inhibitor of USP7, elevates p53 levels and apoptosis in cancer cells and also exhibits tumor suppressive activity in xenograft multiple myeloma and B-cell leukemia models [213]. Many DUBs such as USP10, USP11, USP24, USP29, and USP42 directly contribute to p53 function by stabilizing p53 protein abundance [214–220]. On the contrary, USP2a negatively regulates p53 protein levels by promoting Mdm2-and MdmX-mediated p53 ubiquitination [221,222]. Several other DUBs such as USP5, USP15, and USP26 also negatively regulate p53 and its functions [223–225].

TGF-\( \beta \) is an oncogenic factor that plays a role in tissue homeostasis and cancer. The TGF-\( \beta \) signaling pathway is tightly regulated by both ubiquitination and deubiquitination [226,227]. E3 ligases such as SMAD7-SMAD specific E3 ubiquitin protein ligase 2 (SMURF2) interacts with the TGF-\( \beta \) receptor complex to facilitate TGF-\( \beta \) ubiquitination [227]. USP15 binds to the SMURF2 complex and prevents ubiquitination of the TGF-\( \beta \) receptor resulting in elevated TGF-\( \beta \) signaling. The expression profile of USP15 is amplified in breast cancer, ovarian cancer, and glioblastoma, which has been found to be correlated with high TGF-\( \beta \) signaling. Depleting USP15 showed reduced oncogenic capacity in patient-derived glioma-initiating cells, suggesting the therapeutic importance of USP15 [227]. UCH37 is another deubiquitinase that positively regulates type I TGF-\( \beta \) receptor and promotes TGF-\( \beta \) signaling in cancer [228]. USP2a, USP4, USP9X, and OTUB1 are additional deubiquitinas that are involved in the activation of TGF-\( \beta \) signaling and therefore TGF-\( \beta \)-mediated pathogenesis of different cancer types [229]. Thus, DUBs have been shown to regulate the activity of oncogenes and tumor suppressor proteins making DUBs a potential target of therapeutic interest.

7.1. DUBs and DNA repair

One hallmark of cancer is genomic instability, which is the predisposition to accumulate damaged DNA. Several exogenous and endogenous factors such as ROS, metabolic by-products, UV radiation, and other genotoxic chemicals generate different types of DNA defects [230]. DNA repair pathways and damage response mechanisms are
broadly regulated by UPS and DUBs, which can be targeted for selective anticancer therapies [231, 232]. USP1 selectively hydrolyses mono-ubiquitin adducts from FANCD2 and subsequently stabilizes Chk1 in the DNA damage response (DDR) [160, 233]. Moreover, USP1 also regulates inhibitors of DNA (ID) binding protein stability that maintains the fate of stem cells [235, 236]. The catalytic activity of USP1 also promotes in vitro transformation of osteosarcoma cells and in vivo tumor formation in murine models [235]. USP1 inhibitor screening showed ML323 as a potential USP1/UAF1 complex inhibitor that potentiates cisplatin cytotoxicity along with increased PCNA and FANCD2 monoubiquitination [237, 238]. Another DUB, USP3, is a chromatin modifier that regulates ubiquitination of the H2A and H2B histones. RNAi-mediated ablation of USP3 leads to the accumulation of DNA breakage and thus replication stress by delaying progression of the S-phase during cell division [239]. USP9X is an interactor and stabilizer of CLASPIN protein that functions in checkpoint responses and replication fork stabilization [240]. It also prevents ubiquitin-mediated degradation of Mcl-1, resulting in enhanced radio resistance in glioblastoma cells [241]. Inhibition of USP9X increased cisplatin and doxorubicin sensitivity in estrogen receptor-negative breast cancer cells and hepatocellular carcinoma cells, respectively [215, 242]. USP7 and USP11 are linked to oncogene-induced senescence wherein they modulate the ubiquitination status of Polycomb group (PcG) proteins that function in transcriptional regulation. Both USP7 and USP11 are recruited at chromatin sites and interact with PcG proteins to regulate the tumor suppressor gene locus p16 INK4A [243]. Additionally, USP11 regulates BRCA2 stability in the DSB repair pathway of homologous recombination, and USP11-depleted cells have been shown to be more sensitive to DNA damaging agents such as mitomycin [244, 245]. USP47 has also been identified as a deubiquitinase critical for DNA repair and maintenance of genome integrity via DNA polymerase (Polβ) deubiquitination [246]. P22077-mediated inhibition of USP47 exerts cytotoxicity in leukemia cells both in vitro and in vivo [246].

7.2. DUBs and cell cycle regulation

The importance of DUBs in cell cycle progression is facilitated by the fact that DUBs are integral components of core cell cycle machinery and cell cycle checkpoints. DUBs control the activity of several E3 ligases in cell cycle progression. USP7 associates with the E3 ligase Mdm2 and its substrate p53, where depletion of USP7 triggers auto-ubiquitination and degradation of Mdm2. The premature degradation of Mdm2 impairs p53 ubiquitination leading to cell cycle arrest at either the G1 or G2 phases [247, 248].

DUBs also regulate chromatin structure and transcription to exert cell cycle control. Under stress conditions, forkhead transcription factor (Foxo4) protein is ubiquitinated and translocated to the nucleus. The activated Foxo4 protein allows for transcription of the CDK-inhibitor p27 leading to cell cycle arrest. USP7 deubiquitinates Foxo4 protein under normal conditions, ensuring transient arrest of the cell cycle [249, 250]. USP28 is a critical component of DNA damage checkpoints and also regulates the stability of c-Myc to maintain the proliferative functions of c-Myc protein in tumor cells [177, 181]. Histone H2A deubiquitination by DUBs facilitate histone phosphorylation and chromosomal segregation. DUBs such as USP3, Usp16/Ub-M, and Ubpb deubiquitinate H2A and are required for mitotic progression [239, 251–253]. USP13, USP39, and USP48 regulate Aurora B kinase levels and are therefore essential for spindle checkpoint integrity during mitosis [254–256].

8. Stress: DUBs activity and its association with cancer

Hypoxia is a common characteristic of cancer that results from increased oxygen consumption by proliferating cancer cells. Hypoxic tension in the tumor microenvironment initiates several signaling cascades, EMT and ROS production. A number of individual DUBs are independently regulated by hypoxia or ROS resulting in the progression of several disorders, particularly cancer.
8.1. Hypoxia: DUBs and cancer

Targeting hypoxia induced ROS in breast cancer cells using the antioxidant NAC reduced hypoxia-mediated cell adhesion and metastasis [257]. Treating cells with NAC also attenuated hypoxia-mediated EGFR activation, suggesting a potential role of redox signaling in hypoxic conditions [257]. Hypoxia-induced ROS also activates HIF1α via inactivation of the HIF1α inhibitor, Prolyl Hydroxylase Domain (PHD) protein [258]. ROS-activated HIF1α in sub-lethally damaged tumor cells contributes to their malignance and survival by promoting the expression of HIF1α-driven genes [259]. ROS activated HIF1α drives the expression of VEGF and allows tumor growth and angiogenesis [260]. Further, the oncogenic potential of HIF1α is attributed by the activation of proliferative genes such as c-Myc and cyclin D1 [261] (Fig. 3).

Several E3 ligases and DUBs regulate the cellular abundance of HIF1α protein in an oxygen-dependent and -independent manner [262]. The von Hippel-Lindau protein (VHL) E3 ligase mediates oxygen-dependent degradation of HIF proteins [263], while DUBs such as USP8, USP9X, USP20, and UCHL1 abrogate VHL-mediated protein degradation of HIF in an oxygen-dependent manner [264–266]. DUBs are involved in oxygen-independent HIF protein stability where hypoxia-induced K63-polyubiquitination of USP7 deubiquitinated HIF1α leading to metastasis and tumor progression [267]. Similarly, USP19 has been shown to regulate hypoxia pathways, including HIF1α, and regulate their abundance [174]. USP28 antagonizes Fbw7-mediated ubiquitination of HIF1α and influences HIF1α-dependent cellular events such as angiogenesis and cell migration [268]. Overall, the list of DUBs regulating HIF1α both in an oxygen-dependent and -independent manner is summarized in Fig. 3.

Conversely, hypoxia can also regulate DUBs by altering DUB mRNA levels. Several melanoma cell lines showed reduced USP13 mRNA and protein expression when exposed to 2% oxygen [269]. Cell-specific regulation of USP28 under hypoxic conditions has also been observed in A549 lung cancer cells [270]. Likewise, USP46 exhibited reduced mRNA expression under hypoxic conditions. USP46 reduction destabilizes the PHLP2 phosphatase, which subsequently leads to hypoxia-induced chemoresistance in colon cancer [271]. Hypoxia-mediated induction of USP47 promotes EMT in colorectal cancer by transcriptional regulation of SNAIL expression [272]. Thus, the role of DUBs and hypoxia in cancer is also an important aspect in tumor biology and other hypoxia associated diseases. Further studies are necessary to forward the use of DUBs as a potential target for the development of DUB-based therapies.

8.2. ROS: DUBs and cancer

Oxidative stress and its influence on altering DUB activity have been associated with several diseases, especially neurological disorders such as Alzheimer’s disease, Parkinson’s disease, and epilepsy [273–276]. Reduced DUB activity is one of the main factors observed in neurodegenerative disorders that affect ubiquitin signal-mediated synaptic functions [276]. Another important factor is aging, where neurodegenerative disorders become predominant due to the accumulation of ROS from damaged mitochondria and increased susceptibility of redox-sensitive DUBs towards oxidation [277]. However, the extent of oxidative stress that can alter DUB activity and its functions in disease progression are yet to be explored.

Apart from their role in neurological disorders, several redox-sensitive DUBs are also involved in cancer. For instance, redox-sensitive DUBs such as USP7 and A20 are associated with the progression of leukemia, liver, and metastatic cancers [278,279]. DUBs also regulate tumor progression by stabilizing potential cancer checkpoints and T-cell functions in cancer immunity. USP9X, CSN5, USP22, and OTUB1 have been found to regulate the crucial PD-1/PD-L1 immune checkpoint in cancer [280–283]. Many DUBs such as USP7, USP8, USP9X, USP11, USP15, CYLD, and A20 are involved in T-cell function and the immune response [284–287]. Moreover, studies understanding the impact of oxidative stress on PD-L1 have identified 15 drugs modulating ROS levels and PD-L1 in cancer cells [288]. The unified scenario integrating the regulation of DUBs by ROS in cancer immune checkpoints is still not understood. Additionally, DUBs such as CYLD, A20, OTUB1, USP7, and USP8, which are the main regulators of PD-1/PD-L1 cancer checkpoint and the immune response, are independently regulated by ROS suggesting a link between ROS regulation of DUBs and cancer checkpoints.

Therefore, DUBs are a promising target to design new anticancer therapies. Small molecule inhibitors (VLX1570) against DUBs such as USP14 and UCHL5 are under clinical trial for the treatment of multiple myeloma [289,290]. Malfunction of USP30 results in the accumulation of non-functional mitochondria in Parkinson’s disease; however, the USP30 inhibitor was shown to be successful in the induction of mitophagy without side-effects [291]. Several drugs targeting the proteasome and DUBs in cancer therapy that are either under pre-clinical or clinical trials are summarized in Table 1. The proteasome inhibitor bortezomib has completed phase IV clinical trials in 18 Taiwanese patients with multiple myeloma (NCT02268890). Another study for bortezomib treatment in 50 participants with multiple myeloma has completed phase II clinical trials to evaluate the efficacy and safety of weekly administration of the drug (NCT01090921). Curcumin, which has been reported to dysregulate UPS has also been extensively studied under clinical settings for cancer (NCT03211104, NCT02944578, NCT03980509).

The natural compound ‘Curcuscone D’ was found to have a synergistic effect with bortezomib and exhibits ROS-induced DUB inhibitory functions leading to the suppression of multiple myeloma cell growth [292]. Likewise, USP2 plays a key role in prostate and breast cancer cell survival [293,294]. Moreover, the small molecule inhibitor beta-lapachone is a potent drug that inhibits USP2 and is under clinical trial [295]. The beta-lapachone mechanism of action is based on selective and non-reversible oxidation of active site catalytic Cys moieties in DUBs [296]. Another DUB, USP14, is correlated with melanoma progression and low survival rate in metastatic melanoma patients [297]. Knockdown of USP14 rapidly accumulates poly-ubiquitinated proteins and chaperones, triggering mitochondrial dysfunction, ER stress, and ROS

| Table 1  | Anticancer drugs targeting UPS and DUBs. |
|----------|----------------------------------------|
| Drug     | Mode of action                         | Cancer type             | Reference   |
| Bortezomib | Proteasome inhibitor, Increase ROS generation | Multiple myeloma, acute myeloid leukemia | [308, 309] |
| Curcumin  | Increase ROS generation, Proteasome inhibitor, CSN5 mediated PD-L1 inhibition | Leukemia                | [280, 310, 311] |
| Piperlongumine | Ubiquitin proteasome system inhibitor, Increase cellular ROS levels | Breast cancer           | [312] |
| b-AP15    | DUB inhibitor, inhibit USP14 and UCH37, Caspase activation, Increase ROS generation | Prostate cancer, p53-deficient tumors | [298, 300, 313] |
| Pimozide  | Increase ROS generation, ID1 degradation through USP1 inhibition | Prostate cancer, leukemia, lung cancer | [314-316] |
| beta-lapachone | Increase ROS generation, inhibit USP2 | Prostate cancer, leukemia | [293, 295, 296] |
| Curcuscione D | Ubiquitin proteasome system inhibitor, Increase ROS generation | Multiple myeloma | [292] |
| Spautin-1  | Induce ROS-mediated DNA damage, target USP10 and USP13 | Malignant melanoma | [317] |
| Pristimerin | ROS-dependent Ubiquitin-proteasomal degradation of BCL2 | Prostate cancer | [318] |

The unified cancer checkpoint in cancer therapy that are either under pre-clinical or clinical trials are summarized in Table 1. The proteasome inhibitor bortezomib has completed phase IV clinical trials in 18 Taiwanese patients with multiple myeloma (NCT02268890). Another study for bortezomib treatment in 50 participants with multiple myeloma has completed phase II clinical trials to evaluate the efficacy and safety of weekly administration of the drug (NCT01090921). Curcumin, which has been reported to dysregulate UPS has also been extensively studied under clinical settings for cancer (NCT03211104, NCT02944578, NCT03980509).
Redox Biology 48 (2021) 102194

9

9

production that results in caspase-independent cell death [297]. Pharmacologic inhibition of USP14 using b-AP15 leads to apoptosis in several human cancer cell lines by decreasing cell viability and increasing ROS generation [298–300].

9. Future directions and conclusion

The altered cellular redox environment in cancer cells makes them more susceptible to redox manipulations and opens the door to the development of redox-based therapeutics to selectively target cancer
cells. Drug advances in anticancer therapies based on oxidative damage through the accumulation of ROS or defective antioxidant systems to alter redox homeostasis are summarized in Table 2. However, despite several pre-clinical and clinical trials of redox-mediated therapeutics, the significance of PTMs of redox-sensitive proteins and their therapeutic implications have not been well characterized. This review summarizes the pro-tumorigenic role of ROS in various cell signaling cascades and mainly emphasizes the ROS-mediated regulation of DUB activity in cancer progression (Fig. 4).

Advancements in ‘omics’ have identified many Cys-modified proteins, including kinases, SUMO, ubiquitin, and DUBs, regulated by oxidation [301,302]. Similar to that of PTPs, the transient and reversible oxidation of catalytic Cys residues in the active site of DUBs exhibits additional control over their activity. Oxidative regulation of DUB activity has several implications in microbial infection, developmental growth control, inflammation, neurodegenerative diseases, and cancer progression [140,273,303,304]. Several bodies of evidence suggest that oxidative stress-mediated DUB regulation can be exploited for therapeutic interventions of various disorders, including cancer. For instance, silencing of USP17, a critical regulator of the cell cycle [305], prevents the progression of lung, breast, and prostate cancer by inducing apoptosis [23,306]. Moreover, depletion of USP17 exerts anticancer effects by downregulation of NF-κB/p65 expression and tumor proliferation by enhancing ROS production, which were reversed using the ROS scavenger NAC [306]. Additionally, the monoubiquitination of PCNA recruits low-fidelity DNA polymerases and initiates DNA damage tolerance in response to oxidative stress in dividing cells [164,307]. The ROS-mediated reversible inactivation of USP1 exubiquitinating activity ensures the rapid accumulation of monoubiquitinated PCNA and subsequent DNA damage response during S-phase [143,150].

Altogether, DUBs belonging to the Cys protease family act as “ROS sensors” in human cells, wherein ROS-mediated DUB inactivation can serve as a critical mechanism for fine-tuning stress-activated signaling cascades. However, this area of research is in its infancy, and several criteria have to be considered in order to fully understand the implication of DUBs in redox-based therapeutics. Importantly, we need to understand how DUB activity is regulated by oxidative stress, particularly the structural information of DUBs revealing the extent of sensitivity towards oxidation or reduction. Secondly, specific information regarding DUBs localization and tissue expression could allow for the prediction of DUB sensitivity level towards stress. Lastly, development of allosteric drugs that modulate DUB function would increase the knowledge to protect any particular DUB from oxidative stress. Overall, the application of transcriptomic, protein structural analysis, and bioinformatics analysis could facilitate our understanding and reveal the mechanisms behind redox-based DUB regulation. Increasing progress in defining the regulation of Cys-based proteases and elucidating their role in human diseases would provide new insight into DUB-oriented therapeutics.

Authors’ contributions
SR and AT conceived the idea. AT wrote the main manuscript along with the assistance of SR and SH. All authors read and approved the final draft of the manuscript.

Funding
This work was supported by grants from the National Research Foundation of Korea (2017M3A9E4048172, 2017M3A9C6061361 and 2021M3A9H3015389).

Declaration of competing interest
The authors declare that they have no competing interests.

Acknowledgments
We would like to thank members of Suri laboratory for their helpful insights.

References
[1] Z.W. Ye, et al., Oxidative stress, redox regulation and diseases of cellular differentiation, Biochim. Biophys. Acta 1850 (8) (2015) 1607–1621.
[2] M. Valko, et al., Role of oxygen radicals in DNA damage and cancer incidence, Mol. Cell. Biochem. 266 (1–2) (2004) 37–56.
[3] M. Valko, et al., Free radicals and antioxidants in normal physiological functions and human disease, Int. J. Biochem. Cell Biol. 39 (1) (2007) 44–84.
[4] S.R. Maxwell, G.Y. Lip, Free radicals and antioxidants in cardiovascular disease, Br. J. Clin. Pharmacol. 44 (4) (1997) 307–317.
[5] W. Droge, Free radicals in the physiological control of cell function, Physiol. Rev. 82 (1) (2002) 47–95.
[6] J. Kim, J. Kim, J.S. Bae, ROS homeostasis and metastasis: a metabolic criterion for cancer therapy, Exp. Mol. Med. 48 (11) (2016) e269.
[7] S.P. Hanessian, I.J. Hosenfeld, C.C. Harris, Radical causes of cancer, Nat. Rev. Cancer 3 (4) (2003) 276–285.
[8] L. Afnan et al., Signaling of reactive oxygen and nitrogen species in Diabetes mellitus, Oxid. Med. Cell. Longev. 3 (6) (2010) 361–373.
[9] R.N. Ames, M.K. Shigenaga, T.M. Hagen, Oxidants, antioxidants, and the degenerative diseases of aging, Proc. Natl. Acad. Sci. U. S. A. 90 (17) (1993) 7915–7922.
[10] T.P. Szatrowski, C.F. Nathan, Production of large amounts of hydrogen peroxide by human tumor cells, Cancer Res. 53 (3) (1993) 794–798.
[11] N.K. Tonks, Redox redux: revisiting PTOPS and the control of cell signaling, Cell 121 (5) (2005) 667–670.
[12] F. Bassermann, R. Eichner, M. Pagano, The ubiquitin proteinosome system - implications for cell cycle control and the targeted treatment of cancer, Biochim. Biophys. Acta 1843 (1) (2014) 150–162.
[13] R.W. King, M. Glotzer, M.W. Kirschner, Mutagenic analysis of the destruction signal of mitotic cyclins and structural characterization of ubiquitinated intermediates, Mol. Biol. Cell 7 (9) (1996) 1343–1357.
[14] Y.C. Wang, S.E. Peterson, J.F. Loring, Protein post-translational modifications and regulation of pluriptopy in human stem cells, Cell Res. 24 (2) (2014) 143–160.
[15] A.M. Antao, et al., Advances in deubiquitinating enzyme inhibition and applications in cancer therapeutics, Cancers 12 (6) (2020).
[16] D. Nandi, et al., The ubiquitin-proteasome system, J. Biocsi. 31 (1) (2006) 137–155.
[17] D. Komaner, M. Rape, The ubiquitin code, Annu. Rev. Biochem. 81 (2012) 203–229.
[18] R. Yau, M. Rape, The increasing complexity of the ubiquitin code, Nat. Cell Biol. 18 (6) (2016) 579–586.
[19] K.N. Swartz, D. Komaner, Ubiquitin modification, Cell Res. 26 (4) (2016) 399–422.
[20] C.M. Pickart, Ubiquitin enters the new millennium, Mol. Cell. 8 (3) (2001) 499–504.
[21] C.M. Pickart, M.J. Eddins, Ubiquitin: structures, functions, mechanisms, Biochim. Biophys. Acta 1695 (1–3) (2004) 55–72.
[22] P. Schwertman, S. Bekker-Jensen, N. Mailand, Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers, Nat. Rev. Mol. Cell. Biol. 17 (6) (2016) 397–394.
[23] C. McFarlane, et al., The deubiquitinating enzyme USP17 is associated with non-small cell lung cancer (NSCLC) recurrence and metastasis, Oncotarget 4 (10) (2013) 1836–1843.
[24] J.H. Suh, et al., NADPH oxidase 1 activity and ROS generation are regulated by grb2/cbl-mediated proteasomal degradation of NoxO1 in colon cancer cells, Cancer Res. 76 (4) (2016) 855–865.
[25] H. Qian, et al., Structure and function of HECT E3 ubiquitin ligases and their role in oxidative stress, J. Transl. Int. Med. 8 (2) (2020) 71–79.
[26] M. Dauggaard, et al., Hac1 controls ROS generation of Rac1-dependent NADPH oxidase complexes, Nat. Commun. 4 (2013) 2180.
[27] B. Chance, H. Sies, A. Boveris, Hydroperoxide metabolism in mammalian organs, Physiol. Rev. 59 (3) (1979) 527–605.
[28] P.K. Jensen, Antimycin-insensitive oxidation of succinate and reduced nicotinamide-adenine dinucleotide in electron-transport particles. I. pH dependency and hydrogen peroxide formation, Biochim. Biophys. Acta 122 (2) (1966) 157–166.
[29] R.S. Balaban, S. Nemoto, T. Finkel, Mitochondria, oxidants, and aging, Cell 120 (4) (2005) 483–495.
[30] W. Drayna, et al., Mitochondrial superoxide production, Exp. Gerontol. 45 (7–8) (2010) 466–472.
[31] R.Z. Zhao, et al., Mitochondrial electron transport chain, ROS generation and uncoupling (Review), Int. J. Mol. Med. 44 (1) (2019) 3–15.
[32] Y.S. Bae, et al., Regulation of reactive oxygen species generation in cell signaling, Mol. Cell. 32 (6) (2011) 491–509.
A. Tyagi et al.

[67] S. Verma, et al., Matrix metalloproteinases and gastrointestinal cancers: impacts and implications.

[68] S. Reuter, et al., Oxidative stress, inflammation, and cancer: how are they linked?

[65] N. Kundu, S. Zhang, A.M. Fulton, Sublethal oxidative stress inhibits tumor cell proliferation and migration.

[62] D. Zhu, et al., The ROS-mediated activation of STAT-3/VEGF signaling is involved in the development of esophageal cancer.

[61] J.A. North, A.A. Spector, G.R. Buettner, Cell fatty acid composition affects free radical production.

[58] H. Lauschke, et al., Lipid peroxidation as additional marker in patients with colorectal cancer.

[55] H.W. Gardner, Oxygen radical chemistry of polyunsaturated fatty acids, Free Radic. Biol. Med. 23 (2) (1997) 347–355.

[54] J.D. Lambeth, NOX enzymes and the biology of reactive oxygen, Nat. Rev. Immunol. 4 (3) (2004) 181–190.

[53] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[52] H. Bjorbaek, et al., Stomach cancer: a review of evidence for a role of reactive oxygen and nitrogen species.

[51] J.A. North, A.A. Spector, G.R. Buettner, Cell fatty acid composition affects free radical production.

[50] J.R. Harrison, et al., PPAR-α-mediated antioxidant defense and regulation of cancer cell death.

[49] J.A. North, A.A. Spector, G.R. Buettner, Cell fatty acid composition affects free radical production.

[48] J. Zhang, et al., ROS and inflammation.

[47] J.D. Lambeth, NOX enzymes and the biology of reactive oxygen, Nat. Rev. Immunol. 4 (3) (2004) 181–190.

[46] K. Bedard, K.H. Krause, The NOX family of ROS-generating NADPH oxidases: overview and implications.

[45] J.D. Lambeth, NOX enzymes and the biology of reactive oxygen, Nat. Rev. Immunol. 4 (3) (2004) 181–190.

[44] K. Bedard, K.H. Krause, The NOX family of ROS-generating NADPH oxidases: overview and implications.

[43] J.D. Lambeth, NOX enzymes and the biology of reactive oxygen, Nat. Rev. Immunol. 4 (3) (2004) 181–190.

[42] J.A. North, A.A. Spector, G.R. Buettner, Cell fatty acid composition affects free radical production.

[41] A. Baracca, et al., Mitochondrial Complex I decrease is responsible for reduced aerobic glycolysis and mitochondrial repression through the Dlx-2/Snail signaling pathway.

[40] A. Baracca, et al., Mitochondrial Complex I decrease is responsible for reduced aerobic glycolysis and mitochondrial repression through the Dlx-2/Snail signaling pathway.

[39] P.E. Porporato, et al., Mitochondrial metabolism and cancer, Cell Res. 28 (3) (2018) 243–256.

[38] M. Jastroch, et al., Mitochondrial proton and electron leaks, Essays Biochem. 47 (2010) 389–399.

[37] P.E. Porporato, et al., Mitochondrial metabolism and cancer, Cell Res. 28 (3) (2018) 243–256.

[36] M. Jastroch, et al., Mitochondrial proton and electron leaks, Essays Biochem. 47 (2010) 389–399.

[35] R. Guo, et al., Architecture of human mitochondrial respiratory megacomplex I(2)VI(2) mitochondrial proton and electron leaks, Essays Biochem. 47 (2010) 389–399.

[34] R. Guo, et al., Architecture of human mitochondrial respiratory megacomplex I(2)VI(2) mitochondrial proton and electron leaks, Essays Biochem. 47 (2010) 389–399.

[33] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[32] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[31] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[30] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[29] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[28] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[27] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[26] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[25] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[24] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[23] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[22] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[21] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[20] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[19] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[18] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[17] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[16] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[15] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[14] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[13] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[12] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[11] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[10] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[9] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[8] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[7] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[6] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[5] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[4] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[3] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[2] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.

[1] H. Wiseman, B. Halliwell, Damage to DNA by reactive oxygen and nitrogen species: a review.
F. Ikeda, I. Dikic, Atypical ubiquitin chains: new molecular signals.

J. Stanicka, et al., NADPH oxidase-generated hydrogen peroxide induces DNA

M. van Huizen, M. Kikkert, The role of atypical ubiquitin chains in the regulation

E.B. Dammer, et al., Polyubiquitin linkage profiles in three models of proteolytic

J. Liang, et al., MCP-induced protein 1 deubiquitinates TRAF proteins and

S.H. Lecker, A.L. Goldberg, W.E. Mitch, Protein degradation by the ubiquitin-

F.E. Reyes-Turcu, K.H. Ventii, K.D. Wilkinson, Regulation and cellular roles of

H.A. Lindner, Deubiquitination in virus infection, Virology 362 (2007) 1–1738.

[106] Y.Y. Huo, et al., PTEN deletion leads to deregulation of antioxidants and increased oxidative damage in mouse embryonic fibroblasts, Free Radic. Biol. Med. 44 (8) (2008) 858–865.

[107] L.Z. Liu, et al., Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K in human ovarian cancer cells, Free Radic. Biol. Med. 41 (10) (2006) 1521–1533.

[108] V.O. Okoh, et al., Reactive oxygen species via redox signaling to PI3K/AKT pathway contribute to the malignant growth of 4-hydroxy estradiol-transformed mammary epithelial cells, PLoS One 5 (12) (2010) e15016.

[109] P.P. Roux, J. Bennis, ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions, Microbiol. Mol. Biol. Rev. 68 (2) (2004) 320–344.

[110] J.A. McCulley, et al., Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance, Biochim. Biophys. Acta 1773 (8) (2007) 1263–1284.

[111] M. Cargnello, P.P. Roux, Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases, Microbiol. Mol. Biol. Rev. 75 (1) (2011) 50–83.

[112] Y. Son, et al., Mitogen-activated protein kinases and reactive oxygen species: how can ROS activate MAPK pathways? J. Signal Transduct. 2011 (2011) 784236.

[113] K. Irani, et al., Mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts, Science 275 (5306) (1997) 1649–1652.

[114] S. Messina, G. De Simone, P. Anczery, Cysteine-based regulation of redox-sensitive Ras small GTPases, Redox Biol. 26 (2019) 101282.

[115] G.Y. Liou, et al., Mutant KRas-induced mitochondrial oxidative stress in pancreatic cancer cells upregulates EGF signaling to drive formation of pancreatic precancerous lesions, Cell Rep. 14 (10) (2016) 2325–2336.

[116] X. Wang, et al., STAT3 inhibition, a novel approach to enhancing targeted therapy addicted tumors, Redox Biol. 25 (2019) 101073.

[117] H. Yu, D. Parshol, R. Jove, STATs in cancer inflammation and immunity: a leading role for STAT5, Nat. Rev. Cancer 9 (11) (2009) 798–809.

[118] C. Kim, et al., Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model, Cancer Lett. 431 (2018) 123–141.

[119] G. Sehli, et al., Inhibition of STAT3 dimers by synthesis and acetylation by gancin suppresses the growth of human hepatocellular carcinoma in vitro and in vivo, Mol. Cancer 13 (2014) 66.

[120] L. Lu, et al., Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote tamoxifen resistance in breast cancer cell lines and overcome of radioresistance with niclosamide, Oncogene 37 (29) (2018) 5292–5300.

[121] J. Stanicka, et al., NADPH oxidase-generated hydrogen peroxide induces DNA damage in mutant FLT3-expressing leukemia cells, J. Biol. Chem. 290 (15) (2015) 9348–9361.

[122] J.F. Woolley, et al., H2O2 production downstream of FLT3 is mediated by p22phox in the endosomal reticulum and is required for STAT5 signalling, PLoS One 7 (7) (2012) e34050.

[123] A. Hershko, et al., Components of ubiquitin-protein lysosome system, Regulation, affinity purification, and role in protein breakdown, J. Biol. Chem. 258 (13) (1983) 8206–8214.

[124] F. Ledda, I. Dikic, Atypical ubiquitin chains: new molecular signals. ‘Protein Modifications: beyond the Usual Suspects’ review series, EMBO Rep. 9 (6) (2008) 536–542.

[125] E.B. Dammer, et al., Polyubiquitin linkage profiles in three models of proteostatic stress suggest the etiology of Alzheimer disease, J. Biol. Chem. 286 (12) (2011) 10457–10465.

[126] M. van Huizen, M. Kikkert, The role of atypical ubiquitin chains in the regulation of the antiviral innate immune response, Front. Cell. Dev. Biol. 7 (2019) 392.

[127] S.H. Leecker, A.L. Goldberg, W.E. Mitch, Protein degradation by the ubiquitin-proteasome pathway in normal and disease states, J. Am. Soc. Nephrol. 17 (7) (2006) 1807–1819.

[128] J. Heidecker, I.E. Wertz, DUBs, the regulation of cell identity and disease, Biochem. J. 467 (1) (2015) 191–204.

[129] F.E. Reyes-Turcu, K.H. Ventii, K.D. Wilkinson, Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes, Annu. Rev. Biochem. 78 (2009) 363–397.

[130] S.A. Abdul Rahman, et al., MNDY-1 is a member of an evolutionarily and structurally distinct new family of deubiquitinating enzymes, Mol. Cell. 63 (2016) 146–155.

[131] T. Herrmann, et al., A family of unconventional deubiquitinases with modular chain specificities determines, Nat. Commun. 4 (2013) 1814.

[132] J. Liang, et al., MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-kappaB signaling, J. Exp. Med. 207 (10) (2010) 2359–2372.

[133] A. Guterman, M.H. Glickman, Complementary roles for Rpn11 and Ubp6 in deubiquitination and proteolysis by the proteasome, J. Biol. Chem. 279 (2004) 1729–1738.

[134] G. Strebbe, K. Hunjakk, I. Dikic, The spatial and temporal organization of ubiquitin networks, Nat. Rev. Mol. Cell Biol. 12 (5) (2011) 295–307.

[135] B. Skag, X. Jiang, Z.J. Chen, The role of ubiquitin in NF-kappaB regulatory pathways, Annu. Rev. Biochem. 78 (2009) 769–796.

[136] H.A. Lindner, Deubiquitination in virus infection, Virology 362 (2) (2007) 245–252.
A. Troilo, et al., HIF1

Z. Li, et al., VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates

I. Azimi, et al., Hypoxia-induced reactive oxygen species mediate N-cadherin and

A. Wyce, et al., H2B ubiquitylation acts as a barrier to Ctk1 nucleosomal

R.S. Wu, K.W. Kohn, W.M. Bonner, Metabolism of ubiquitinated histones, J. Biol. Chem. 256 (11) (1981) 5916–5920.

J.R. Kowalski, P. Juo, The role of deubiquitinating enzymes in synaptic function

M. Scortegagna, et al., USP13 enzyme regulates Siah2 ligase stability and activity

S. Vlasschaert, et al., Evolution of the highly networked deubiquitinating

M. Zhao, et al., Non-proteolytic ubiquitination of OTULIN regulates NF-B signaling pathway, J. Mol. Cell. Biol. 12 (3) (2020) 163–175.

H. Luo, et al., Pharmacological inhibition of USP30 activates tissue-specific

E. Graner, et al., The isopeptidase USP2a regulates the stability of fatty acid

S. A. 105 (46) (2008) 17724–17727.

R.E. Savage, et al., Identification of a novel glycosyltransferase conjugate as a metabolite of 3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione (ARQ 501, beta-lapachone) in mammals, Drug Metab. Dispos. 36 (4) (2008) 753–758.

S. Ohayon, et al., Harnessing the oxidation susceptibility of deubiquitinas for inhibition with small molecules, Angew. Chem. Int. Ed. 54 (2015) 99–103.

R. Didier, et al., Targeting the proteasome-associated deubiquitinating enzyme USP14 improves melanoma cell survival and overcomes resistance to MAPK-targeting therapies, Mol. Cancer Therapeutics. 17 (7) (2018) 1416–1429.

J. Cai, et al., A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers, Oncotarget 8 (38) (2017) 63232–63246.

Y. Yang, et al., The antioxidant alpha-lipoic acid inhibits proliferation and invasion of human gastric cancer cells via suppression of STAT3-mediated MUC4 expression, Oncotarget 7 (37) (2016) 60519–60533.

E. Meulmeester, et al., Loss of HAUSP-mediated deubiquitination contributes to breast cancer through the cell cycle, Oncogene 39 (37) (2020) 6009–6023.

H.Y. Joo, et al., Regulation of cell cycle progression and gene expression by H2A deubiquitinase, Nature 449 (7165) (2007) 1068–1072.

J. Vlasschaert, et al., Evolution of the highly networked deubiquitinating

M. Zhao, et al., Non-proteolytic ubiquitination of OTULIN regulates NF-B signaling pathway, J. Mol. Cell. Biol. 12 (3) (2020) 163–175.

C. Bailly, Regulation of PD-1 expression on cancer cells with ROS-modulating drugs, Life Sci. 246 (2020) 117403.

E.K. Rowinsky, et al., Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma, Invest. N. Drugs 38 (5) (2010) 1448–1453.

X. Wang, et al., Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15, Chem. Biol. Drug Des. 86 (5) (2015) 1036–1046.

H. Liao, et al., Pharmacological inhibition of USP30 activates tissue-specific

S. Ohayon, et al., Harnessing the oxidation susceptibility of deubiquitinas for inhibition with small molecules, Angew. Chem. Int. Ed. 54 (2015) 99–103.

R. Didier, et al., Targeting the proteasome-associated deubiquitinating enzyme USP14 improves melanoma cell survival and overcomes resistance to MAPK-targeting therapies, Mol. Cancer Therapeutics. 17 (7) (2018) 1416–1429.

J. Cai, et al., A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers, Oncotarget 8 (38) (2017) 63232–63246.

Y. Yang, et al., The antioxidant alpha-lipoic acid inhibits proliferation and invasion of human gastric cancer cells via suppression of STAT3-mediated MUC4 expression, Oncotarget 7 (37) (2016) 60519–60533.

E. Graner, et al., The isopeptidase USP2a regulates the stability of fatty acid

S. A. 105 (46) (2008) 17724–17727.

R.E. Savage, et al., Identification of a novel glycosyltransferase conjugate as a metabolite of 3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione (ARQ 501, beta-lapachone) in mammals, Drug Metab. Dispos. 36 (4) (2008) 753–758.

S. Ohayon, et al., Harnessing the oxidation susceptibility of deubiquitinas for inhibition with small molecules, Angew. Chem. Int. Ed. 54 (2015) 99–103.

R. Didier, et al., Targeting the proteasome-associated deubiquitinating enzyme USP14 improves melanoma cell survival and overcomes resistance to MAPK-targeting therapies, Mol. Cancer Therapeutics. 17 (7) (2018) 1416–1429.

J. Cai, et al., A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers, Oncotarget 8 (38) (2017) 63232–63246.

Y. Yang, et al., The antioxidant alpha-lipoic acid inhibits proliferation and invasion of human gastric cancer cells via suppression of STAT3-mediated MUC4 expression, Oncotarget 7 (37) (2016) 60519–60533.

E. Graner, et al., The isopeptidase USP2a regulates the stability of fatty acid

S. A. 105 (46) (2008) 17724–17727.

R.E. Savage, et al., Identification of a novel glycosyltransferase conjugate as a metabolite of 3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione (ARQ 501, beta-lapachone) in mammals, Drug Metab. Dispos. 36 (4) (2008) 753–758.

S. Ohayon, et al., Harnessing the oxidation susceptibility of deubiquitinas for inhibition with small molecules, Angew. Chem. Int. Ed. 54 (2015) 99–103.

R. Didier, et al., Targeting the proteasome-associated deubiquitinating enzyme USP14 improves melanoma cell survival and overcomes resistance to MAPK-targeting therapies, Mol. Cancer Therapeutics. 17 (7) (2018) 1416–1429.

J. Cai, et al., A novel deubiquitinase inhibitor b-AP15 triggers apoptosis in both androgen receptor-dependent and -independent prostate cancers, Oncotarget 8 (38) (2017) 63232–63246.

Y. Yang, et al., The antioxidant alpha-lipoic acid inhibits proliferation and invasion of human gastric cancer cells via suppression of STAT3-mediated MUC4 expression, Oncotarget 7 (37) (2016) 60519–60533.
[313] Y.S. Ma, et al., Inhibition of USP14 and UCH37 deubiquitinating activity by b-APl5 as a potential therapy for tumors with p53 deficiency, Signal Transduct. Target Ther. 5 (1) (2020) 30.

[314] U. Kim, et al., Pimozide inhibits the human prostate cancer cells through the generation of reactive oxygen species, Front. Pharmacol. 10 (2019) 1517.

[315] J. Chen, et al., Selective and cell-active inhibitors of the USP1/UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells, Chem. Biol. 18 (11) (2011) 1390–1400.

[316] H. Mistry, et al., Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells, Mol. Cancer Therapeut. 12 (12) (2013) 2651–2662.

[317] J. Guo, et al., Potent USP10/13 antagonist spautin-1 suppresses melanoma growth via ROS-mediated DNA damage and exhibits synergy with cisplatin, J. Cell Mol. Med. 24 (7) (2020) 4324–4340.

[318] X.B. Liu, et al., Pristimerin induces apoptosis in prostate cancer cells by down-regulating bcl-2 through ROS-dependent ubiquitin-proteasomal degradation pathway, J. Carcinog. Mutagen. (Suppl 6) (2013), 005.

[319] S. Kotamraju, et al., Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis, J. Biol. Chem. 277 (19) (2002) 17179–17187.

[320] J. Lankelma, et al., Doxorubicin gradients in human breast cancer, Clin. Cancer Res. 5 (7) (1999) 1703–1707.

[321] R. Marullo, et al., Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions, PLoS One 8 (11) (2013) e81162.

[322] S. Dasari, P.B. Tchounwou, Cisplatin in cancer therapy: molecular mechanisms of action, Eur. J. Pharmacol. 740 (2014) 364–378.

[323] D. Magda, R.A. Miller, Motexafin gadolinium: a novel redox active drug for cancer therapy, Semin. Cancer Biol. 16 (6) (2006) 466–476.

[324] G.M. Richards, M.P. Mehta, Motexafin gadolinium in the treatment of brain metastases, Expert Opin. Pharmacother. 8 (3) (2007) 351–358.

[325] T. Hagen, et al., Inhibition of mitochondrial respiration by the anticancer agent 2-methoxyestradiol, Biochem. Biophys. Res. Commun. 322 (3) (2004) 923–929.

[326] M. Fuku, B.T. Zhu, Mechanism of 2-methoxyestradiol-induced apoptosis and growth arrest in human breast cancer cells, Mol. Carcinog. 48 (1) (2009) 66–78.

[327] S. Qanungo, et al., 2-Methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells, Oncogene 21 (26) (2002) 4149–4157.

[328] E.W. Griffith, A. Meister, Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine), J. Biol. Chem. 254 (16) (1979) 7558–7560.

[329] M. Lee, et al., 3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells, PLoS One 12 (3) (2017) e0174271.

[330] S. Moulder, et al., A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer, Invest. N. Drugs 28 (5) (2010) 634–640.

[331] E.V. Sheveleva, et al., Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells, Mol. Cancer Res. 10 (3) (2012) 392–400.

[332] B. Kim, et al., Peroxiredoxin 5 overexpression enhances tumorigenicity and correlates with poor prognosis in gastric cancer, Int. J. Oncol. 51 (1) (2017) 298–306.

[333] A. Nicoluzi, et al., The role of peroxiredoxins in cancer, Mol. Clin. Oncol. 6 (2) (2017) 139–153.

[334] E. Lu, et al., Up-regulation of peroxiredoxin-1 promotes cell proliferation and metastasis and inhibits apoptosis in cervical cancer, J. Cancer 11 (5) (2020) 1170–1181.

[335] W. Fiskus, et al., SIRT2 deacetylates and inhibits the peroxidase activity of peroxiredoxin-1 to sensitize breast cancer cells to oxidant stress-inducing agents, Cancer Res. 76 (18) (2016) 5467–5478.